ESR1 and triple-negative breast carcinoma: Conversely, triple-negative breast cancer (TNBC) represents cancers lacking clinical expression of ERα, progesterone receptor (PR), and HER2 (ER-/PR-/HER2-) and cannot be treated with current endocrine or HER2-targeted therapies.